Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Crescendo Bioscience logo — Empowering rheumatologists with precise diagnostic tools for...

Crescendo Bioscience

Empowering rheumatologists with precise diagnostic tools for autoimmune and inflammatory disease management.

Founded 2002 1001-5000 employees Series D Total: $141.68M Biotechnology, Health Care

General Information

Company Name Crescendo Bioscience
Founded Year 2002
Employees 1001-5000
Industries Biotechnology, Health Care
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Crescendo Bioscience. To contact Crescendo Bioscience, visit crescendobio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Crescendo Bioscience compare?

A PDF of Crescendo Bioscience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Crescendo Bioscience soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Crescendo Bioscience

Crescendo Bioscience, with the slogan "Empowering rheumatologists with precise diagnostic tools for autoimmune and inflammatory disease management," was founded in 2002 in South San Francisco, California. The company, originally known as Riley Genomics, Inc., focuses on creating diagnostic, prognostic, staging, therapy selection, and monitoring solutions for physicians dealing with autoimmune and inflammatory conditions. In January 2013, Crescendo Bioscience secured a noteworthy $28.00M Series D investment from a group of prominent investors including Kleiner Perkins, Mohr Davidow Ventures, Skyline Ventures, Safeguard Scientifics, and Aeris Capital. Crescendo Bioscience’s mission to provide rheumatologists with precise diagnostic tools for managing autoimmune and inflammatory diseases aligns with the increasing demand for innovative healthcare solutions. The company's focus on biotechnology and healthcare industries positions it to capitalize on the growing need for advanced diagnostic and therapeutic solutions in the medical field. With its strong investor backing, the company is well-positioned to further develop and commercialize its diagnostic tools, potentially driving impactful advancements in autoimmune and inflammatory disease management.

Business keywords: Molecular Diagnostics, Personalized Medicine, Prognostic Medicine, Companion Diagnostics, Pharmacogenomics, Genetic Testing, Hereditary Cancer, Precision Medicine, Rheumatology, Autoimmune Diseases, Inflammatory Diseases, Diagnostic Tools, South San Francisco

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $28.00M 5
Kleiner Perkins Mohr Davidow Ventures Skyline Ventures
Kleiner Perkins, Mohr Davidow Ventures +3
03 Jan 2013
Debt Financing $25.00M 1
Myriad Genetics
20 Sep 2011
Series C $31.00M 4
Kleiner Perkins Mohr Davidow Ventures TriplePoint Capital
Kleiner Perkins, Mohr Davidow Ventures +2
08 Sep 2011
Series B $37.60M 2
Kleiner Perkins Mohr Davidow Ventures
Kleiner Perkins, Mohr Davidow Ventures
07 Jul 2010
Series B $15.00M 2
Kleiner Perkins Mohr Davidow Ventures
Kleiner Perkins, Mohr Davidow Ventures
27 Jun 2008
Series A $5.08M 1
Mohr Davidow Ventures
Mohr Davidow Ventures
19 Mar 2007

Crescendo Bioscience Alternatives & Competitors

View All Alternatives
Crescendo Bioscience vs
Genekor Medical S.A.
Genekor Medical S.A. Greece

Committed to Biotechnological Innovation.

88 employees
Biotechnology, Health Care
Crescendo Bioscience vs
Metamark Genetics
Metamark Genetics United States

Metamark - A leader in comprehensive urology cancer care

Growth
23 employees
Biotechnology, Health Care
Crescendo Bioscience vs
mdxhealth
mdxhealth United States

Molecular Diagnostic Solutions for Prostate Cancer

Post-IPO Equity
262 employees
Biotechnology, Health Care
Also compare with: Crescendo Bioscience vs Prometheus Biosciences, Inc. Prometheus Biosciences, Inc. View all alternatives

FAQ About Crescendo Bioscience

Empowering rheumatologists with precise diagnostic tools for autoimmune and inflammatory disease management.
Crescendo Bioscience was founded in 2002.
Crescendo Bioscience operates in Biotechnology and Health Care. Its work centres on Molecular Diagnostics, Personalized Medicine, Prognostic Medicine and Companion Diagnostics.
Crescendo Bioscience has approximately 1001-5000 employees.
Crescendo Bioscience has completed 6 funding rounds, raising a total of $141.68M. The latest funding stage is Series D.
Top alternatives and competitors to Crescendo Bioscience include Genekor Medical S.A., Metamark Genetics, mdxhealth, SeqOne, xMD Diagnostics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Crescendo Bioscience and Genekor Medical S.A. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Crescendo Bioscience, https://bouncewatch.com/company/crescendo-bioscience, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes